Assessing uptake of the macular degeneration core outcome set in clinical trials: a cross-sectional study
Eli Oldham, R Hunter Hall, Garrett Jones, Jay Modi, Shaelyn Ward, Trevor Magee, Kyle Fitzgerald, Kimberly Magana, Griffin Hughes, Alicia Ito Ford, Matthew Vassar · 2025
Read Assessing uptake of the macular degeneration core outcome set in clinical trials: a cross-sectional study by Eli Oldham, R Hunter Hall, Garrett Jones, Jay Modi, Shaelyn Ward, Trevor Magee, Kyle Fitzgerald, Kimberly Magana, Griffin Hughes, Alicia Ito Ford, Matthew Vassar (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12742102.txt.
Description
Eli Oldham leads a team of eleven in a 2025 study on whether eye trials use the agreed outcome set for macular degeneration. A core outcome set lists the measures every trial of a disease should report, so results can be compared. Uptake of the eye set had not been gauged.
The team pulled more than two thousand registered trials from a public registry and kept 159 that fit their rules. They then checked how many reported the core measures, and whether use rose after the set came out. A time-series read found no clear jump. Traits of the trials were also weighed against how fully they used the set.
Catalog record
| CREATOR | Eli Oldham, R Hunter Hall, Garrett Jones, Jay Modi, Shaelyn Ward, Trevor Magee, Kyle Fitzgerald, Kimberly Magana, Griffin Hughes, Alicia Ito Ford, Matthew Vassar |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |